Zeria Pharmaceutical Co., Ltd. (4559.T)
JPY 2454.0
(1.95%)
JPY 2454.0
(1.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 17.52 Billion JPY | 22.8% |
| 2022 | 13.75 Billion JPY | 20.71% |
| 2021 | 11.43 Billion JPY | 48.44% |
| 2020 | 8.63 Billion JPY | -3.54% |
| 2019 | 8.09 Billion JPY | 12.56% |
| 2018 | 9.15 Billion JPY | -20.77% |
| 2017 | 9.61 Billion JPY | 7.35% |
| 2016 | 8.98 Billion JPY | 8.15% |
| 2015 | 8.67 Billion JPY | 38.31% |
| 2014 | 6.73 Billion JPY | -41.25% |
| 2013 | 10.17 Billion JPY | 23.97% |
| 2012 | 9.14 Billion JPY | -0.96% |
| 2011 | 8.2 Billion JPY | 26.34% |
| 2010 | 6.02 Billion JPY | 47.07% |
| 2009 | 4.27 Billion JPY | 13.34% |
| 2008 | 4.49 Billion JPY | -21.67% |
| 2007 | 5.1 Billion JPY | -7.09% |
| 2006 | 5.39 Billion JPY | 50.85% |
| 2005 | 3.81 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.82 Billion JPY | 324.23% |
| 2023 Q1 | 3.46 Billion JPY | 400.0% |
| 2023 FY | - JPY | 22.8% |
| 2023 Q3 | 4.06 Billion JPY | 80.4% |
| 2023 Q2 | 2.25 Billion JPY | -34.93% |
| 2023 Q4 | 2.46 Billion JPY | -39.45% |
| 2022 Q3 | 1.85 Billion JPY | -19.26% |
| 2022 Q1 | 3.05 Billion JPY | 654.38% |
| 2022 FY | - JPY | 20.71% |
| 2022 Q4 | 693.28 Million JPY | -62.73% |
| 2022 Q2 | 2.3 Billion JPY | -24.71% |
| 2021 Q3 | 2.58 Billion JPY | 131.63% |
| 2021 FY | - JPY | 48.44% |
| 2021 Q1 | 2.15 Billion JPY | 828.49% |
| 2021 Q2 | 1.11 Billion JPY | -48.22% |
| 2021 Q4 | 405.61 Million JPY | -84.28% |
| 2020 Q3 | 2.28 Billion JPY | 212.04% |
| 2020 FY | - JPY | -3.54% |
| 2020 Q1 | 693.41 Million JPY | -19.73% |
| 2020 Q4 | -295.3 Million JPY | -112.93% |
| 2020 Q2 | 731.75 Million JPY | 5.53% |
| 2019 Q4 | 863.82 Million JPY | -42.92% |
| 2019 Q3 | 1.51 Billion JPY | 626.38% |
| 2019 Q2 | 208.34 Million JPY | -87.04% |
| 2019 FY | - JPY | 12.56% |
| 2019 Q1 | 1.6 Billion JPY | 204.89% |
| 2018 FY | - JPY | -20.77% |
| 2018 Q4 | 527.29 Million JPY | -44.87% |
| 2018 Q3 | 956.4 Million JPY | 331.14% |
| 2018 Q2 | 221.83 Million JPY | -87.61% |
| 2018 Q1 | 1.79 Billion JPY | 629.11% |
| 2017 Q4 | 245.5 Million JPY | -89.82% |
| 2017 FY | - JPY | 7.35% |
| 2017 Q3 | 2.41 Billion JPY | 25.3% |
| 2017 Q2 | 1.92 Billion JPY | 173.39% |
| 2017 Q1 | 703.82 Million JPY | -29.31% |
| 2016 Q2 | 1.31 Billion JPY | -30.67% |
| 2016 Q1 | 1.9 Billion JPY | 148.86% |
| 2016 Q4 | 995.67 Million JPY | 104.02% |
| 2016 Q3 | 488.03 Million JPY | -63.0% |
| 2016 FY | - JPY | 8.15% |
| 2015 Q3 | 2.26 Billion JPY | 112.54% |
| 2015 Q1 | 643.32 Million JPY | 224.5% |
| 2015 FY | - JPY | 38.31% |
| 2015 Q4 | 764.55 Million JPY | -66.26% |
| 2015 Q2 | 1.06 Billion JPY | 65.73% |
| 2014 FY | - JPY | -41.25% |
| 2014 Q3 | 1.14 Billion JPY | -15.49% |
| 2014 Q2 | 1.35 Billion JPY | 35.29% |
| 2014 Q1 | 998.93 Million JPY | 25.56% |
| 2014 Q4 | -516.71 Million JPY | -145.24% |
| 2013 FY | - JPY | 23.97% |
| 2013 Q4 | 795.55 Million JPY | -58.3% |
| 2013 Q3 | 1.9 Billion JPY | 58.71% |
| 2013 Q2 | 1.2 Billion JPY | -61.73% |
| 2013 Q1 | 3.14 Billion JPY | 192.89% |
| 2012 Q3 | 1.72 Billion JPY | 71.33% |
| 2012 Q4 | 1.07 Billion JPY | -37.85% |
| 2012 Q2 | 1 Billion JPY | -13.09% |
| 2012 FY | - JPY | -0.96% |
| 2012 Q1 | 1.15 Billion JPY | 863.93% |
| 2011 Q1 | 1.65 Billion JPY | 24.99% |
| 2011 FY | - JPY | 26.34% |
| 2011 Q2 | 1.1 Billion JPY | -32.99% |
| 2011 Q3 | 2.1 Billion JPY | 89.77% |
| 2011 Q4 | -151.7 Million JPY | -107.21% |
| 2010 Q1 | 1.21 Billion JPY | 37.99% |
| 2010 Q4 | 1.32 Billion JPY | -18.0% |
| 2010 Q2 | 2.05 Billion JPY | 68.51% |
| 2010 FY | - JPY | 47.07% |
| 2010 Q3 | 1.61 Billion JPY | -21.51% |
| 2009 Q4 | 884.09 Million JPY | -19.27% |
| 2009 Q3 | 1.09 Billion JPY | -18.49% |
| 2009 Q2 | 1.34 Billion JPY | 51.45% |
| 2009 Q1 | 887.06 Million JPY | 7.13% |
| 2009 FY | - JPY | 13.34% |
| 2008 Q2 | 725.49 Million JPY | 0.0% |
| 2008 Q3 | 731.33 Million JPY | 0.81% |
| 2008 FY | - JPY | -21.67% |
| 2008 Q4 | 828.04 Million JPY | 13.22% |
| 2007 FY | - JPY | -7.09% |
| 2006 FY | - JPY | 50.85% |
| 2005 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -191.009% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 97.997% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 106.234% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 90.615% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -2968.74% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 51.718% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | -42.836% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 83.006% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -1255.116% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 4.462% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | -95.271% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -377.429% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -1148.87% |
| Tsumura & Co. | 30.77 Billion JPY | 43.06% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 6.401% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -232.416% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 50.693% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -154.601% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | -70.179% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 567.244% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -131.983% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 2554.012% |
| MedRx Co., Ltd | -884.51 Million JPY | 2080.93% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -216.487% |
| Solasia Pharma K.K. | -635 Million JPY | 2859.314% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 838.088% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | -91.222% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 52.481% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 3355.063% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 32.205% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -243.451% |